Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the united states during an influenza pandemic

Dhankhar, Praveen; Grabenstein, John D.; O’Brien, Megan A.; Dasbach, Erik J.

doi:10.1016/j.clinthera.2010.07.019

Cited by 13 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the annual influenza vaccination coverage rate is not monitored regularly, the need for the influenza vaccine seems to be increasing since the 2009 influenza pandemic. However, previous studies on the effectiveness of the influenza vaccine reported conflicting results, especially in the elderly [ 4 – 6 ]. Considering the large supply of influenza vaccine in Korea, a regular and accurate assessment is needed.…”

Section: Introductionmentioning

confidence: 99%

Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations

et al. 2015

View full text Add to dashboard Cite

BackgroundThe effectiveness of the 2011–2012 seasonal influenza vaccine was evaluated in adult Korean populations with regard to how well it could prevent laboratory-confirmed influenza and influenza-related complications.Materials and MethodsA retrospective case-control and retrospective cohort study was conducted among patients who visited four selected hospitals from September 2011 to May 2012. The analysis included 1,130 laboratory-confirmed influenza patients. For each influenza case, one control patient was chosen at a ratio of 1:1. A control was defined as an age group-matched patient who visited the same hospital with influenza-like illness within 48 hours of symptom onset but for whom laboratory tests were negative for influenza. Age group and visit date were matched between the cases and controls. Vaccine effectiveness (VE) was defined as [100 × (1-odds ratio for influenza in vaccinated versus non-vaccinated persons)]. The patients with laboratory-confirmed influenza were followed for at least one month through reviewing the medical records and conducting a telephone interview.ResultsThe VE of the 2011–2012 seasonal influenza vaccine was 3.8% [95% confidence interval (CI), -16.5% to 20.6%] for preventing laboratory-confirmed influenza, -16.1% (95% CI, -48.3 to 9.1) for influenza A and 26.2% (95% CI, -2.6 to 46.2) for influenza B. The age-specific adjusted VE was 0.3% (95% CI, -29.4 to 23.1) among participants aged 19 to 49 years, 11.9% (95% CI, -34.3 to 42.2) among those aged 50 to 64 years and -3.9% (-60.1 to 32.5) among those aged ≥65 years. The adjusted VE for preventing any influenza-related complications was -10.7% (95% CI, -41.1% to 42.2%).ConclusionsThe 2011–2012 seasonal influenza vaccine was not effective in preventing laboratory-confirmed influenza or influenza-related complications in adult Korean populations.

show abstract

Section: Introductionmentioning

confidence: 99%

Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The most commonly captured benefit from the broad perspective was outcome-related productivity gains. Sixteen studies (10.7%) included this benefit [ 74 – 76 , 81 , 85 , 87 , 98 , 108 , 115 , 117 , 127 , 132 , 142 , 144 , 157 , 165 ]. These studies estimated how much work individuals miss due to a case of pneumococcal disease and compute the value of that missed work by multiplying missed time by the wage rate.…”

Section: Resultsmentioning

confidence: 99%

“…For example, of the 17 unique studies that account for at least one broad benefit, seven (41.2%) present only study abstracts [ 75 , 81 , 85 , 87 , 98 , 115 , 144 ]. Of the remaining 10 studies [ 74 , 76 , 108 , 117 , 127 , 132 , 142 , 157 , 160 , 165 ], other limitations abound, including, for example, borrowing epidemiological trend data from other countries [ 108 ], lack of data necessitating many assumptions and low estimate precision [ 157 ], and possible confounding due to a study’s observational nature [ 160 ].…”

Section: Resultsmentioning

confidence: 99%

The full benefits of adult pneumococcal vaccination: A systematic review

et al. 2017

View full text Add to dashboard Cite

BackgroundPneumococcal disease causes substantial morbidity and mortality, including among adults. Adult pneumococcal vaccines help to prevent these burdens, but they are underused. Accounting for the full benefits of adult pneumococcal vaccination may promote more rational resource allocation decisions with respect to adult pneumococcal vaccines.ObjectivesUsing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a systematic review to assess the extent to which the literature has empirically captured (e.g., through measurement or modeling) the full benefits of adult pneumococcal vaccination.MethodsWe systematically searched PubMed and Embase to identify studies published between January 1, 2010 and April 10, 2016 that examine adult pneumococcal vaccination. We included articles if they captured any health or economic benefit of an adult pneumococcal vaccine administered to adults age ≥ 50 or ≥ 18 in risk groups. Finally, we summarized the literature by categorizing the types of benefits captured, the perspective taken, and the strength of the evidence presented. Our protocol is number 42016038335 in the PROSPERO International prospective register of systematic reviews.ResultsWe identified 5,857 papers and included 150 studies for analysis. While most capture health gains and healthcare cost savings, far fewer studies consider additional benefit categories, such as productivity gains. However, the studies with a broader approach still exhibit significant limitations; for example, many present only abstracts, while others offer no new measurements. Studies that examine the 13-valent pneumococcal conjugate vaccine focus more on broad economic benefits, but still have limitations.ConclusionsThis review highlights the need for more robust empirical accounting of the full benefits of adult pneumococcal vaccination. Literature outside this realm indicates that these broad benefits may be substantial. Failing to investigate the full benefits may lead society to undervalue vaccines' contributions and therefore underinvest in their development and adoption.

show abstract

“…Mass vaccination was cost-effective and depended on the timing of vaccination and vaccine effectiveness [27]. Vaccination and stockpiling pneumococcal vaccine for the time of in uenza pandemic are also very cost-effective [28,46].…”

Section: Stockpiling Vaccines and Vaccinationmentioning

confidence: 99%

“…For severe pandemics or pandemics in which pre-pandemic in uenza vaccine is unavailable, stockpiling of 23-valent pneumococcal polysaccharide vaccine (PPSV23) for a pneumococcal disease can be a cost-effective strategy for reducing the health and economic burden associated with secondary pneumococcal infections in a high-risk population. However, for a mildly severe pandemic in which pre-pandemic in uenza vaccine is available, stockpiling of PPSV23 may not be cost-effective [28]. The cost-effectiveness of vaccine stockpile is determined by the vaccine e cacy and strain match and the costs of the vaccine.…”

Section: Stockpiling Vaccines and Vaccinationmentioning

confidence: 99%

An economic evaluation of Influenza and COVID -19 pandemic prevention and control interventions: a systematic review

Yigezu¹,

Yitayal²,

Mirkuzie³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: COVID-19 causes more 1.3 million deaths globally in just nine months. Influenza is a virus with respiratory symptoms, fever, and systemic symptoms very similar to COVID 19. Various public health measures have been taken by governments and health authorities to prevent and control the pandemics. This study aimed to review the economic evaluation of public health measures against COVID-19 and influenza pandemics.Methods: We performed a systematic review of the literature to identify full economic evaluation studies on Influenza and COVID-19 pandemic published from 1998-2020. We built an exhaustive database search strategy. The search was done in Pubmed, Web of Science, EMBASE databases, and grey literature. We extracted data from selected studies using a structured data collection form after conducting a risk of bias assessment. Narrative summary tables were used to present the result and characteristics of eligible studies. Furthermore, we converted findings of studies that reported their outcome in costs per case averted and death averted into costs per life-year gained. All cost and Cost-effectiveness ratios were converted to 2019 US dollars using the exchange rate and GDP deflator. The study was registered in PROSPERO with registration No. CRD42020192384.Results: The review revealed that most of the studies were conducted in high-income countries, and only few of the studies were on non-pharmaceutical interventions. Stockpiling drugs for the treatment of sick patients was found cost-effective in most of the studies. Treatment with antiviral drugs and vaccination were found very cost-effective. The addition of school closure to other interventions was considered cost-effective only for a pandemic with a high case fatality ratio. Almost all interventions were sensitive to the infectivity and severity of the pandemic. Most of the studies were also cost-effective from the societal perspective indicating a higher net societal benefit from the pandemic prevention and control strategies.Conclusion: In conclusion, most of the interventions were cost-effective under various scenarios while school closure was cost-effective under a 'high case-fatality 'ratio' scenario only. Furthermore, the level of the pandemic's infectivity and severity were the key drivers of the cost-effectiveness of both pharmaceutical and non-pharmaceutical interventions.

show abstract

Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the united states during an influenza pandemic

Cited by 13 publications

References 22 publications

Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations

Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations

The full benefits of adult pneumococcal vaccination: A systematic review

An economic evaluation of Influenza and COVID -19 pandemic prevention and control interventions: a systematic review

Contact Info

Product

Resources

About